Skip to main content
Erschienen in:

21.08.2024 | Review

Prognostic significance of CRLF2 in patients with acute lymphoblastic leukemia: a meta-analysis and systematic review

verfasst von: Zilu Meng, Hanxue Zheng, Yang Liu, Xiaojia Guo, Songlin Chu, Wen Zhou, Yanhong Li, Jun Bai, Liansheng Zhang, Lijuan Li

Erschienen in: Annals of Hematology | Ausgabe 11/2024

Einloggen, um Zugang zu erhalten

Abstract

The association between cytokine receptor-like factor 2 (CRLF2) and clinical outcomes in acute lymphoblastic leukemia (ALL) has been a topic of ongoing debate, with divergent findings. This article intended to investigate the influence of CRLF2 alterations on ALL prognosis. Following the PRISMA 2020 guidelines, this meta-analysis was conducted. Hazard ratio (HR) values and confidence intervals (CIs) were the primary statistical measures used. Data heterogeneity was judged using the chi-square test and I2 statistic. Publication bias was appraised with funnel plots, Begg's test, and Egger's test. 16 studies with 6771 patients were finally screened out. CRLF2 over-expression (CRLF2 OE) was associated with poorer event-free survival (EFS) (HR = 1.70, 95% CI = 1.18–2.44, P = 0.004) and relapse-free survival (RFS) (HR = 1.70, 95% CI = 1.28–2.24, P = 0.000) in pediatric ALL. Patients with CRLF2-deregulation (CRLF2-d), also known as CRLF2 rearrangement, exhibited shorter overall survival (OS) (HR = 2.22, 95% CI = 1.49–3.32, P = 0.000), EFS (HR = 1.93, 95% CI = 1.43–2.60, P = 0.000), and RFS (HR = 2.2, 95% CI = 1.53–3.18, P = 0.000) compared to those without CRLF2-d. Subgroup analysis of multivariate HRs and corresponding CIs indicated that childhood with CRLF2 OE had a shorter RFS (HR = 1.70, 95% CI = 1.28–2.24, P = 0.006), and CRLF2-d was identified as an independent prognostic biomarker for OS (HR = 2.22, 95% CI = 1.49–3.32, P = 0.000), EFS (HR = 1.95, 95% CI = 1.44–2.64, P = 0.000), and RFS (HR = 2.2, 95% CI = 1.53–3.18, P = 0.000) in pediatric ALL patients. Both CRLF2 OE and CRLF2-d are associated with poor prognosis in ALL patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Pui CH, Mullighan CG, Evans WE, Relling MV (2012) Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 120:1165–1174CrossRefPubMedPubMedCentral Pui CH, Mullighan CG, Evans WE, Relling MV (2012) Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 120:1165–1174CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Schrappe M, Reiter A, Zimmermann M et al (2000) Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster Leukemia 14:2205–2222PubMed Schrappe M, Reiter A, Zimmermann M et al (2000) Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster Leukemia 14:2205–2222PubMed
3.
Zurück zum Zitat Möricke A, Reiter A, Zimmermann M et al (2008) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111:4477–4489CrossRefPubMed Möricke A, Reiter A, Zimmermann M et al (2008) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111:4477–4489CrossRefPubMed
4.
Zurück zum Zitat Stanulla M, Cavé H, Moorman AV (2020) IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? Blood 135:252–260CrossRefPubMedPubMedCentral Stanulla M, Cavé H, Moorman AV (2020) IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? Blood 135:252–260CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Hunger SP, Mullighan CG (2015) Acute lymphoblastic leukemia in children. N Engl J Med 373:1541–1552CrossRefPubMed Hunger SP, Mullighan CG (2015) Acute lymphoblastic leukemia in children. N Engl J Med 373:1541–1552CrossRefPubMed
6.
8.
Zurück zum Zitat Lin TS, Mahajan S, Frank DA (2000) STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 19:2496–2504CrossRefPubMed Lin TS, Mahajan S, Frank DA (2000) STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 19:2496–2504CrossRefPubMed
9.
Zurück zum Zitat Mullighan CG, Collins-Underwood JR, Phillips LA et al (2009) Rearrangement of CRLF2 in B-progenitor- and down syndrome-associated acute lymphoblastic leukemia. Nat Genet 41:1243–1246CrossRefPubMedPubMedCentral Mullighan CG, Collins-Underwood JR, Phillips LA et al (2009) Rearrangement of CRLF2 in B-progenitor- and down syndrome-associated acute lymphoblastic leukemia. Nat Genet 41:1243–1246CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Kuang WY, Li WL, Zheng MC et al (2019) [Clinical significance of CRLF2 high expression in bone marrow mononuclear cells from children with acute lymphoblastic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 27:1058–1063PubMed Kuang WY, Li WL, Zheng MC et al (2019) [Clinical significance of CRLF2 high expression in bone marrow mononuclear cells from children with acute lymphoblastic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 27:1058–1063PubMed
11.
Zurück zum Zitat Chapiro E, Russell L, Lainey E et al (2010) Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia 24:642–645CrossRefPubMed Chapiro E, Russell L, Lainey E et al (2010) Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia 24:642–645CrossRefPubMed
12.
Zurück zum Zitat Hertzberg L, Vendramini E, Ganmore I et al (2010) Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 115:1006–1017CrossRefPubMed Hertzberg L, Vendramini E, Ganmore I et al (2010) Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 115:1006–1017CrossRefPubMed
13.
Zurück zum Zitat Russell LJ, Capasso M, Vater I et al (2009) Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 114:2688–2698CrossRefPubMed Russell LJ, Capasso M, Vater I et al (2009) Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 114:2688–2698CrossRefPubMed
14.
Zurück zum Zitat Chen H, Wang XJ, Liu S et al (2018) [The expression of CRLF2 in adult Ph negative acute B lymphocytic leukemia and its prognostic significance]. Zhonghua Xue Ye Xue Za Zhi 39:822–827PubMed Chen H, Wang XJ, Liu S et al (2018) [The expression of CRLF2 in adult Ph negative acute B lymphocytic leukemia and its prognostic significance]. Zhonghua Xue Ye Xue Za Zhi 39:822–827PubMed
15.
Zurück zum Zitat Chen IM, Harvey RC, Mullighan CG et al (2012) Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood 119:3512–3522CrossRefPubMedPubMedCentral Chen IM, Harvey RC, Mullighan CG et al (2012) Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood 119:3512–3522CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Yano M, Imamura T, Asai D et al (2014) An overall characterization of pediatric acute lymphoblastic leukemia with CRLF2 overexpression. Genes Chromosomes Cancer 53:815–823CrossRefPubMed Yano M, Imamura T, Asai D et al (2014) An overall characterization of pediatric acute lymphoblastic leukemia with CRLF2 overexpression. Genes Chromosomes Cancer 53:815–823CrossRefPubMed
17.
Zurück zum Zitat Cario G, Zimmermann M, Romey R et al (2010) Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 115:5393–5397CrossRefPubMed Cario G, Zimmermann M, Romey R et al (2010) Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 115:5393–5397CrossRefPubMed
18.
Zurück zum Zitat Palmi C, Vendramini E, Silvestri D et al (2012) Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 26:2245–2253CrossRefPubMed Palmi C, Vendramini E, Silvestri D et al (2012) Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 26:2245–2253CrossRefPubMed
19.
Zurück zum Zitat Buitenkamp TD, Pieters R, Gallimore NE et al (2012) Outcome in children with Down’s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 26:2204–2211CrossRefPubMed Buitenkamp TD, Pieters R, Gallimore NE et al (2012) Outcome in children with Down’s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 26:2204–2211CrossRefPubMed
20.
21.
Zurück zum Zitat Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed
22.
Zurück zum Zitat Yusuf S, Peto R, Lewis J et al (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335–371CrossRefPubMed Yusuf S, Peto R, Lewis J et al (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335–371CrossRefPubMed
23.
Zurück zum Zitat Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefPubMed Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefPubMed
25.
Zurück zum Zitat Yamashita Y, Shimada A, Yamada T et al (2011) IKZF1 and CRLF2 gene alterations correlate with poor prognosis in BCR-ABL1-negative high risk B-cell precursor acute lymphoblastic leukemia. Blood 118:566CrossRef Yamashita Y, Shimada A, Yamada T et al (2011) IKZF1 and CRLF2 gene alterations correlate with poor prognosis in BCR-ABL1-negative high risk B-cell precursor acute lymphoblastic leukemia. Blood 118:566CrossRef
26.
Zurück zum Zitat Van der Veer A, Waanders E, Pieters R et al (2013) Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 122:2622–2629CrossRefPubMedPubMedCentral Van der Veer A, Waanders E, Pieters R et al (2013) Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 122:2622–2629CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Singh J, Benjamin M, Pandey AK et al (2023) Prognostic relevance of surface expression of cytokine receptor-like factor 2 in pediatric B-lineage acute lymphoblastic leukemia. Am J Cancer Res 13:2452–2470PubMedPubMedCentral Singh J, Benjamin M, Pandey AK et al (2023) Prognostic relevance of surface expression of cytokine receptor-like factor 2 in pediatric B-lineage acute lymphoblastic leukemia. Am J Cancer Res 13:2452–2470PubMedPubMedCentral
28.
Zurück zum Zitat Palmi C, Valsecchi MG, Longinotti G et al (2013) What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? Haematologica 98:1226–1231CrossRefPubMedPubMedCentral Palmi C, Valsecchi MG, Longinotti G et al (2013) What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? Haematologica 98:1226–1231CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Palmi C, Silvestri D, Bronzini I et al (2014) CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Blood 124:1071CrossRef Palmi C, Silvestri D, Bronzini I et al (2014) CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Blood 124:1071CrossRef
30.
Zurück zum Zitat Moorman AV, Schwab C, Ensor HM et al (2012) IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol 30:3100–3108CrossRefPubMed Moorman AV, Schwab C, Ensor HM et al (2012) IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol 30:3100–3108CrossRefPubMed
31.
Zurück zum Zitat Moorman AV, Barretta E, Butler ER et al (2022) Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. Leukemia 36:625–636CrossRefPubMed Moorman AV, Barretta E, Butler ER et al (2022) Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. Leukemia 36:625–636CrossRefPubMed
32.
Zurück zum Zitat Ensor HM, Schwab C, Russell LJ et al (2011) Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 117:2129–2136CrossRefPubMed Ensor HM, Schwab C, Russell LJ et al (2011) Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 117:2129–2136CrossRefPubMed
33.
Zurück zum Zitat Dou H, Chen X, Huang Y et al (2017) Prognostic significance of P2RY8-CRLF2 and CRLF2 overexpression may vary across risk subgroups of childhood B-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 56:135–146CrossRefPubMed Dou H, Chen X, Huang Y et al (2017) Prognostic significance of P2RY8-CRLF2 and CRLF2 overexpression may vary across risk subgroups of childhood B-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 56:135–146CrossRefPubMed
34.
Zurück zum Zitat Dörge P, Meissner B, Zimmermann M et al (2013) IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 98:428–432CrossRefPubMedPubMedCentral Dörge P, Meissner B, Zimmermann M et al (2013) IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 98:428–432CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Jia M, Wang ZJ, Zhao HZ et al (2015) Prognostic significance of cytokine receptor-like factor 2 alterations in acute lymphoblastic leukemia: a meta-analysis. World J Pediatr 11:126–133CrossRefPubMed Jia M, Wang ZJ, Zhao HZ et al (2015) Prognostic significance of cytokine receptor-like factor 2 alterations in acute lymphoblastic leukemia: a meta-analysis. World J Pediatr 11:126–133CrossRefPubMed
36.
Zurück zum Zitat Kołodrubiec J, Kozłowska M, Irga-Jaworska N et al (2022) Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review. Leukemia Res 121 Kołodrubiec J, Kozłowska M, Irga-Jaworska N et al (2022) Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review. Leukemia Res 121
37.
Zurück zum Zitat Niswander LM, Loftus JP, Lainey É et al (2021) Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica 106:2763–2767CrossRefPubMedPubMedCentral Niswander LM, Loftus JP, Lainey É et al (2021) Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica 106:2763–2767CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Tomb PE, Shikdar S, Khawandanah M (2022) ALL-180 a case of refractory Philadelphia-like acute lymphoblastic leukemia treated with ruxolitinib/blinatumomab and ruxolitinib/inotuzumab ozogamicin prior to allogeneic marrow transplant. Clin Lymphoma Myeloma Leuk 22:S195CrossRef Tomb PE, Shikdar S, Khawandanah M (2022) ALL-180 a case of refractory Philadelphia-like acute lymphoblastic leukemia treated with ruxolitinib/blinatumomab and ruxolitinib/inotuzumab ozogamicin prior to allogeneic marrow transplant. Clin Lymphoma Myeloma Leuk 22:S195CrossRef
39.
Zurück zum Zitat Jain N, Lu X, Daver N et al (2017) Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica 102:e514–e517CrossRefPubMedPubMedCentral Jain N, Lu X, Daver N et al (2017) Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica 102:e514–e517CrossRefPubMedPubMedCentral
Metadaten
Titel
Prognostic significance of CRLF2 in patients with acute lymphoblastic leukemia: a meta-analysis and systematic review
verfasst von
Zilu Meng
Hanxue Zheng
Yang Liu
Xiaojia Guo
Songlin Chu
Wen Zhou
Yanhong Li
Jun Bai
Liansheng Zhang
Lijuan Li
Publikationsdatum
21.08.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 11/2024
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-05667-2

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Vorhofflimmern: Antikoagulation vor Schlaganfall von Vorteil

Erleiden Menschen mit Vorhofflimmern einen ischämischen Schlaganfall, ist dieser weniger schwer, auch sind Infarktgröße und Blutungsrisiko geringer, wenn sie zuvor orale Antikoagulanzien erhalten haben. Die Art der Antikoagulation spielt dabei keine Rolle.

HCL-Systeme bei Typ-1-Diabetes: Blutzuckerkontrolle besser, Risiko für Ketoazidose aber höher

Eine bessere Blutzuckerkontrolle und weniger Fälle von hypoglykämischem Koma, dafür mehr diabetische Ketoazidosen. Dieses HCL-Insulin-Therapie-Profil zeigte sich in einem Vergleich von Hybrid-Closed-Loop(HCL)- und Open-Loop-Systemen bei Typ-I-Diabetes im DPV-Register.

Kein (großer) Schutz vor Kolorektalkarzinom-Rezidiven durch ASS

Die erste Phase-3-Studie zum Nutzen von ASS in der adjuvanten Therapie des kolorektalen Karzinoms ist negativ verlaufen. Das abschließende Urteil über eine Sekundärprävention mit ASS ist trotzdem noch nicht gefallen.

Möglicher Zusatzeffekt von SGLT-2-Hemmern und GLP-1-Analoga bei COPD

Menschen mit Typ-2-Diabetes, die gleichzeitig an COPD leiden, könnten von der Behandlung mit SGLT-2-Hemmern und GLP-1-Rezeptoragonisten doppelt profitieren: Eine Analyse aus den USA deutet auf ein vermindertes Exazerbationsrisiko hin.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.